RCT: Therapeutic-dose heparin superior to standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19.
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial – JAMA Internal Medicine Invited commentary: Anticoagulant Therapy in Patients Hospitalized With COVID-19 – JAMA Internal Medicine Related studies (some conflicting results) Another meta-analysis suggests standard-dose prophylactic anticoagulation is the […]
The post RCT: Therapeutic-dose heparin superior to standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19. appeared first on Links Medicus.
Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.
Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England – Eurosurveillance Related: RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination. Heterologous Oxford–AstraZeneca and Moderna Vaccination induce […]
The post Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination. appeared first on Links Medicus.
WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).
A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 – World Health Organization Related: Characterizing long COVID: a living systematic review. Long Covid – The illness narratives. New guidelines to help doctors manage long COVID patients published. M-A: More than 50 long-term effects of COVID-19. (several articles on the subject) […]
The post WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid). appeared first on Links Medicus.
WHO Guidance: Antigen-detection in the diagnosis of SARS-CoV-2 infection.
Antigen-detection in the diagnosis of SARS-CoV-2 infection – World Health Organization Related infographics: Use of antigen detection rapid diagnostic testing – World Health Organization Diagnostic testing for SARS-CoV-2 infection – World Health Organization Commentary on Twitter (thread – click for more) Testing remains a critical component to the strategy to end the #COVID19 pandemic, […]
The post WHO Guidance: Antigen-detection in the diagnosis of SARS-CoV-2 infection. appeared first on Links Medicus.
Ivermectin: How false science created a Covid ‘miracle’ drug.
Ivermectin: How false science created a Covid ‘miracle’ drug – BBC Commentary on Twitter Scientists evaluating ivermectin data for #COVID19"had not found 'a single clinical trial' claiming to show that ivermectin prevented Covid deaths that did not contain 'either obvious signs of fabrication or errors so critical they invalidate the study'." https://t.co/Xndr6Q5LaS — Isaac […]
The post Ivermectin: How false science created a Covid ‘miracle’ drug. appeared first on Links Medicus.
Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high.
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar – New England Journal of Medicine Related: Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 […]
The post Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high. appeared first on Links Medicus.
Systematic review: Pretomanid for tuberculosis.
Pretomanid for tuberculosis: a systematic review – Clinical Microbiology and Infection Related: Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update. WHO announces updates on new molecular assays for the diagnosis of tuberculosis (TB) and drug resistance WHO announces updated definitions of extensively drug-resistant tuberculosis
The post Systematic review: Pretomanid for tuberculosis. appeared first on Links Medicus.
RCT: An active strategy for diagnosing pulmonary embolism did not improve outcomes in patients hospitalized for COPD exacerbation.
Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation: A Randomized Clinical Trial – JAMA (free for a limited period) Commentary on Twitter Among patients hospitalized for an exacerbation of #COPD, addition of an active diagnostic strategy for pulmonary embolism to usual care compared with usual care […]
The post RCT: An active strategy for diagnosing pulmonary embolism did not improve outcomes in patients hospitalized for COPD exacerbation. appeared first on Links Medicus.
Opinion | Why Are Americans Still—Still!—Wearing Cloth Masks?
Why Are Americans Still—Still!—Wearing Cloth Masks? – The Atlantic Related: Evidence shows that, yes, masks prevent COVID-19 – and surgical masks are the way to go. Face masks for COVID pass their largest test yet – “A rigorous study finds that surgical masks are highly protective, but cloth masks fall short”. [Preprint] Largest study of […]
The post Opinion | Why Are Americans Still—Still!—Wearing Cloth Masks? appeared first on Links Medicus.
What we know — and don’t know — about Merck’s new Covid-19 pill.
What we know — and don’t know — about Merck’s new Covid-19 pill – STAT Related: [Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19. Merck’s Covid-19 pill is great news but […]
The post What we know — and don’t know — about Merck’s new Covid-19 pill. appeared first on Links Medicus.